ABN Amro report just released. Move from hold to buy. Still maintaining conservative price target of $2.24. On ABN amro forecasts, BTA is currently trading on an FY10 earnings multiple of just 3.7, FY11 of just 2.9. The analyst is assuming that for FY10 GSK sells only half of the Relenza that it has the capacity to produce.